Latest product updates

Welcome to the Higher Standard.

Explore how Edwards SAPIEN 3 TAVI is designed to meet your Higher Standard.

With so much at stake, there's no room to compromise.

Edwards SAPIEN 3 TAVI helps you:

Delivering the outcomes you demand

1%
death or disabling
stroke 1 year
in low risk patients1,2

Perfect the pathway through efficient procedures

96%
of patients discharged to the
comfort of their own home1

Control for the future to continue to meet the emerging needs of new patient populations

100%
successful post-TAVI
coronary access
(68/68 patients)3

Explore the clinical trials that establish the evidence of Edwards SAPIEN 3 TAVI in patients with severe aortic stenosis.

View PARTNER Trials

Stay informed with our newsletter

References:

1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low Risk Patients. N Engl J Med. 2019;380:1695-1705.
2. Leon MB, Mack MJ. PARTNER 3: Transcatheter or Surgical Aortic-Valve Replacement in Low Risk Patients with Aortic Stenosis. Presented at: ACC 2019; New Orleans, LA.
3. Tarantini G, Fovino LN, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic implantation with a balloon-expandable valve. Circ Cardiovasc Interv. 2020;13(7):e008972.

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

PP--EU-3363 v1.0